In high-risk T2DM, canagliflozin reduced CV events regardless of baseline renal function.

In high-risk T2DM, canagliflozin reduced CV events regardless of baseline renal function.
Ann Intern Med. 2019 Feb 19;170(4):JC15
Authors: Herrington WG, Zhu D, Haynes R
PMID: 30776804 [PubMed - in process]

Source: Annals of Internal Medicine - February 19, 2019 Category: Internal Medicine Authors: Herrington WG, Zhu D, Haynes R Tags: Ann Intern Med Source Type: research